Page 187 - 2020_08-Haematologica-web

Apoptosis induced by selective BH3-mimetics
Building blocks of the apoptotic pore: how Bax and Bak are activated and oligomerize during apoptosis. Cell Death Diff. 2014;21(2):196-205.
31. Liu Y, Mondello P, Erazo T, et al. NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death. Proc Natl Acad Sci U S A. 2018;115(47):12034-12039.
32. KongW,ZhouM,LiQ,FanW,LinH,Wang R. Experimental characterization of the binding affinities between proapoptotic BH3 peptides and antiapoptotic Bcl-2 pro- teins. ChemMedChem. 2018;13(17):1763- 1770.
33. Rooswinkel RW, van de Kooij B, de Vries E, et al. Antiapoptotic potency of Bcl-2 pro- teins primarily relies on their stability, not binding selectivity. Blood. 2014;123(18): 2806-2815.
34. Greaves G, Milani M, Butterworth M, et al. BH3-only proteins are dispensable for apop- tosis induced by pharmacological inhibition of both MCL-1 and BCL-XL. Cell Death Diff. 2019;26(6):1037-1047.
35. Merino D, Whittle JR, Vaillant F, et al. Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-ampli- fied breast cancer. Sci Transl Med. 2017;9(401): eaam7049.
36. Chen HC, Kanai M, Inoue-Yamauchi A, et al. An interconnected hierarchical model of cell death regulation by the BCL-2 family. Nat Cell Biol. 2015;17(10):1270-1281.
37. Du H, Wolf J, Schafer B, Moldoveanu T, Chipuk JE, Kuwana T. BH3 domains other than Bim and Bid can directly activate Bax/Bak. J Biol Chem. 2011;286(1):491-501.
38. Vogler M. BCL2A1: the underdog in the BCL2 family. Cell Death Diff. 2012;19(1):67- 74.
39. Adams CM, Mitra R, Gong JZ, Eischen CM. Non-Hodgkin and Hodgkin lymphomas select for overexpression of BCLW. Clin Cancer Res. 2017;23(22):7119-7129.
40. Th'ng KH, Garewal G, Kearney L, et al. Establishment and characterization of three new malignant lymphoid cell lines. Int J Cancer. 1987;39(1):89-93.
41. Amini RM, Berglund M, Rosenquist R, et al. A novel B-cell line (U-2932) established from a patient with diffuse large B-cell lymphoma following Hodgkin lymphoma. Leuk Lymphoma. 2002;43(11):2179-2189.
42. Tweeddale ME, Lim B, Jamal N, et al. The presence of clonogenic cells in high-grade malignant lymphoma: a prognostic factor. Blood. 1987;69(5):1307-1314.
43. Epstein AL, Levy R, Kim H, Henle W, Henle G, Kaplan HS. Biology of the human malig- nant lymphomas. IV. Functional characteri- zation of ten diffuse histiocytic lymphoma cell lines. Cancer. 1978;42(5):2379-2391.
44. Kubonishi I, Niiya K, Miyoshi I. Establishment of a new human lymphoma line that secretes plasminogen activator. Jpn J Cancer Res. 1985;76(1):12-15.
45. Tohda S, Sato T, Kogoshi H, Fu L, Sakano S, Nara N. Establishment of a novel B-cell lym-
phoma cell line with suppressed growth by gamma-secretase inhibitors. Leuk Res. 2006;30(11):1385-1390.
46. Epstein AL, Variakojis D, Berger C, Hecht BK. Use of novel chemical supplements in the establishment of three human malignant lymphoma cell lines (NU-DHL-1, NU-DUL- 1, and NU-AMB-1) with chromosome 14 translocations. Int J Cancer. 1985;35(5):619- 627.
47. Fridberg M, Servin A, Anagnostaki L, et al. Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: higher expression of ZAP70 and PKC-beta II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN. Leuk Lymphoma. 2007;48(11):2221-2232.
48. Epstein AL, Kaplan HS. Biology of the human malignant lymphomas. I. Establishment in continuous cell culture and heterotransplantation of diffuse histiocytic lymphomas. Cancer. 1974;34(6):1851-1872.
49. Abe M, Nozawa Y, Wakasa H, Ohno H, Fukuhara S. Characterization and compari- son of two newly established Epstein-Barr virus-negative lymphoma B-cell lines. Surface markers, growth characteristics, cytogenetics, and transplantability. Cancer. 1988;61(3):483-490.
50. Gabay C, Ben-Bassat H, Schlesinger M, Laskov R. Somatic mutations and intraclonal variations in the rearranged Vkappa genes of B-non-Hodgkin's lymphoma cell lines. Eur J Haematol. 1999;63(3):180-191.
haematologica | 2020; 105(8)
2163